Clinical trials: Peripheral Primitive Neuroectodermal Tumor
Disseminated Neuroblastoma, Localized Unresectable Neuroblastoma
R(+)XK469 in Treating Patients With Advanced Neuroblastoma
This phase I trial is studying the side effects and best dose of R(+)XK469 in treating patients with advanced neuroblastoma. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop…
- Conditions
- Disseminated Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00028522
- Testing
- R(+)XK469
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Neuroblastoma, Refractory Neuroblastoma
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with dinutuximab with or without isotretinoin in treating younger patients with neuroblastoma that does not respond to treatment or…
- Trial name
- NCT01711554
- Testing
- Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis
- Where
- 15 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Biomarkers in Young Patients With Neuroblastoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01169376
- Testing
- DNA analysis, DNA methylation analysis, RNA analysis
- Volunteers
- 380 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
SF1126 for Patients With Relapsed or Refractory Neuroblastoma
SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues.
- Trial name
- NCT02337309
- Testing
- SF1126
- Where
- 11 sites in United States
- Volunteers
- 4 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Acute Leukemia, Adenomatous Polyposis
Familial Investigations of Childhood Cancer Predisposition
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll.
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML
- Trial name
- SJFAMILY (NCT03050268)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- St. Jude Children's Research Hospital
Neuroblastoma, Rhabdomyosarcoma
A Vaccine Study for High Risk Cancers
The purpose of this study is to determine the safety and immunological effects of a vaccine for people diagnosed with high risk neuroblastoma, osteogenic sarcoma, and rhabdomyosarcoma.
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Osteogenic Sarcoma
- Trial name
- NCT00944580
- Testing
- MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
- Sponsor
- Penn State University
Neuroblastoma
Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00365755
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Sponsor
- Children's Cancer and Leukaemia Group
Neuroblastoma
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
MAGNETO is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractory neuroblastoma.
- Trial name
- MAGNETO (NCT05990751)
- Testing
- GD2 CAR T cells
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College, London
Head and Neck Cancer, Pain
Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer
RATIONALE: Acupuncture may help relieve pain and dysfunction caused by cancer surgery. It is not yet known whether acupuncture is more effective than standard therapy in treating pain and dysfunction in patients who have…
- Trial name
- NCT00090337
- Testing
- acupuncture therapy, standard follow-up care
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as fenretinide LXS, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00295919
- Testing
- fenretinide lipid matrix, ketoconazole, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Pediatric Cancer, Neuroblastoma
Biomarkers of Resiliency In Childhood Cancer Surgery
This observational study is to better understand how children and their families recover after the stress of major surgery for cancer so that investigators can create ways to improve resilience during recovery.
- Conditions
- Pediatric Cancer, Neuroblastoma, Sarcoma, Wilms Tumor and Other Childhood Kidney Tumors
- Trial name
- BRICCS (NCT06674811)
- Testing
- Wearing Smartwatch, Patient Report Outcomes, Blood Draw
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Relapsed Neuroblastoma, Refractory Neuroblastoma
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
This is a Phase 1 study with Phase 2 expansion cohort. Phase 1 will assess the safety and tolerability of universal donor TGFβi NK Cell in combination with irinotecan, temozolomide, and dinituximab.
- Trial name
- STING (NCT04211675)
- Testing
- Natural Killer Cells, Temozolomide, Irinotecan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Nationwide Children's Hospital
Sarcoma
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00470275
- Testing
- cytarabine
- Where
- 73 sites in United States, Australia and 2 more
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Neuroblastoma
Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
This is a single-center, investigator-initiated, single-arm, pilot study of post-allogeneic transplant, adoptive immunotherapy for the treatment of patients with relapsed/refractory neuroblastoma expressing the mesenchymal tumor…
- Trial name
- STALLONe (NCT01460901)
- Testing
- GD2 CAR modified Tri-virus specific cytotoxic t-cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's Mercy Hospital Kansas City
Neuroblastoma, Ewing Sarcoma
Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method
In prepubertal patients, cryopreservation of ovarian or testicular tissue is currently the only available method for fertility preservation prior to gonadotoxic cancer treatments.
- Trial name
- PREFERPUBER (NCT07141862)
- Testing
- RT-qPCR, ddPCR
- Where
- France
- Volunteers
- 89 people
- Sponsor
- University Hospital, Clermont-Ferrand
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults.
- Trial name
- NCT01682746
- Testing
- Photofrin (porfimer sodium) & photodynamic therapy.
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Harry T Whelan, MD
Neuroblastoma
Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Inserting genetic material made in the laboratory into a person's blood cells may make the body build an immune…
- Trial name
- NCT00006480
- Testing
- aldesleukin, therapeutic autologous lymphocytes, chemotherapy
- Where
- 2 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Neuroblastoma, CNS Metastases
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to…
- Conditions
- Neuroblastoma, CNS Metastases, Leptomeningeal Metastases
- Trial name
- NCT03275402
- Testing
- 131I-omburtamab
- Where
- 8 sites in United States, Denmark and 2 more
- Volunteers
- 52 people
- Sponsor
- Y-mAbs Therapeutics
Neuroblastoma
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people…
- Trial name
- N2011-01 (NCT02035137)
- Testing
- 131I-MIBG, Vincristine, Irinotecan
- Where
- 14 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium